Literature DB >> 18828631

Effects of linker length and flexibility on multivalent targeting.

Thomas A Shewmake1, Francisco J Solis, Robert J Gillies, Michael R Caplan.   

Abstract

Increasing valence can enhance the ability of molecular targeting constructs to bind specifically to targeted cells for drug delivery. Here, we mathematically model the length and flexibility of a linker used to conjoin two peptide ligands of a divalent targeting construct and investigate the influence both on binding avidity and specificity. Four different models are used to approximate varying degrees of linker flexibility (random coil, rigid rod, jointed rods, and combined rod-random coil) and for each linker a binding enhancement factor (VR) is derived that quantifies the increased rate of each construct's second binding event over the first. Results indicate that the moderately flexible models can best reproduce experimentally measured avidities. Also, the magnitude of VR, in conjunction with receptor density and ligand concentration, significantly influences the achievable specificity. Thus, the model elucidates important considerations in designing multivalent targeting constructs for use in delivery of targeted therapy or imaging.

Mesh:

Substances:

Year:  2008        PMID: 18828631     DOI: 10.1021/bm800529b

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  19 in total

1.  A sucrose-derived scaffold for multimerization of bioactive peptides.

Authors:  Venkataramanarao Rao; Ramesh Alleti; Liping Xu; Narges K Tafreshi; David L Morse; Robert J Gillies; Eugene A Mash
Journal:  Bioorg Med Chem       Date:  2011-08-27       Impact factor: 3.641

2.  Near-infrared fluorescent divalent RGD ligand for integrin αvβ₃-targeted optical imaging.

Authors:  Yunpeng Ye; Walter Akers; Baogang Xu; Sharon Bloch; Charles Odonkor; Samuel Achilefu
Journal:  Bioorg Med Chem Lett       Date:  2012-07-20       Impact factor: 2.823

3.  The length of glycine-rich linker in DNA-binding domain is critical for optimal functioning of quorum-sensing master regulatory protein HapR.

Authors:  Naorem Santa Singh; Sangita Kachhap; Richa Singh; Rahul Chandra Mishra; Balvinder Singh; Saumya Raychaudhuri
Journal:  Mol Genet Genomics       Date:  2014-07-05       Impact factor: 3.291

Review 4.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

Review 5.  Multivalent Inhibitors of Channel-Forming Bacterial Toxins.

Authors:  Goli Yamini; Ekaterina M Nestorovich
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

6.  Heterobivalent ligands target cell-surface receptor combinations in vivo.

Authors:  Liping Xu; Jatinder S Josan; Josef Vagner; Michael R Caplan; Victor J Hruby; Eugene A Mash; Ronald M Lynch; David L Morse; Robert J Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

7.  Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells.

Authors:  Nathaniel J Hart; Woo Jin Chung; Craig Weber; Kameswari Ananthakrishnan; Miranda Anderson; Renata Patek; Zhanyu Zhang; Sean W Limesand; Josef Vagner; Ronald M Lynch
Journal:  Chembiochem       Date:  2013-11-20       Impact factor: 3.164

8.  Synthesis and bioactivity of MSH4 oligomers prepared by an A2 + B2 strategy.

Authors:  Dilani Chathurika Dehigaspitiya; Suryakiran Navath; Craig S Weber; Ronald M Lynch; Eugene A Mash
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

9.  A solanesol-derived scaffold for multimerization of bioactive peptides.

Authors:  Ramesh Alleti; Venkataramanarao Rao; Liping Xu; Robert J Gillies; Eugene A Mash
Journal:  J Org Chem       Date:  2010-09-03       Impact factor: 4.354

10.  Glioblastoma targeting via integrins is concentration dependent.

Authors:  Elena V Rosca; Robert J Gillies; Michael R Caplan
Journal:  Biotechnol Bioeng       Date:  2009-10-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.